Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage.

Bedke J, Kiss E, Schaefer L, Behnes CL, Bonrouhi M, Gretz N, Horuk R, Diedrichs-Moehring M, Wildner G, Nelson PJ, Gröne HJ.

Am J Transplant. 2007 Mar;7(3):527-37. Epub 2007 Jan 4.

2.

Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.

Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D.

J Am Soc Nephrol. 2004 Jun;15(6):1504-13. Erratum in: J Am Soc Nephrol. 2004 Aug;15(8):following table of contents.

3.

CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.

Horuk R, Shurey S, Ng HP, May K, Bauman JG, Islam I, Ghannam A, Buckman B, Wei GP, Xu W, Liang M, Rosser M, Dunning L, Hesselgesser J, Snider RM, Morrissey MM, Perez HD, Green C.

Immunol Lett. 2001 Apr 2;76(3):193-201.

PMID:
11306147
4.

Protective effects of atorvastatin on chronic allograft nephropathy in rats.

Zhang W, Liu M, Wu Y, Zhu P, Yin C, Zhang W, Gu M.

J Surg Res. 2007 Dec;143(2):428-36. Epub 2007 Jul 12.

PMID:
17628598
5.
6.

Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.

Yun JJ, Whiting D, Fischbein MP, Banerji A, Irie Y, Stein D, Fishbein MC, Proudfoot AE, Laks H, Berliner JA, Ardehali A.

Circulation. 2004 Feb 24;109(7):932-7. Epub 2004 Feb 2.

7.

Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.

Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R, Weber M, Krombach F, Schlöndorff D, Anders HJ.

J Am Soc Nephrol. 2005 Apr;16(4):977-85. Epub 2005 Feb 16.

8.

Expression of the chemokine receptor CCR1 in human renal allografts.

Mayer V, Hudkins KL, Heller F, Schmid H, Kretzler M, Brandt U, Anders HJ, Regele H, Nelson PJ, Alpers CE, Schlöndorff D, Segerer S.

Nephrol Dial Transplant. 2007 Jun;22(6):1720-9. Epub 2007 Feb 13.

PMID:
17298994
9.

Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection.

Le Meur Y, Jose MD, Mu W, Atkins RC, Chadban SJ.

Transplantation. 2002 Apr 27;73(8):1318-24.

PMID:
11981428
10.

A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection.

Horuk R, Clayberger C, Krensky AM, Wang Z, Grone HJ, Weber C, Weber KS, Nelson PJ, May K, Rosser M, Dunning L, Liang M, Buckman B, Ghannam A, Ng HP, Islam I, Bauman JG, Wei GP, Monahan S, Xu W, Snider RM, Morrissey MM, Hesselgesser J, Perez HD.

J Biol Chem. 2001 Feb 9;276(6):4199-204. Epub 2000 Oct 27.

11.

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.

Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Gröne HJ, Schlöndorff D, Anders HJ.

Kidney Int. 2004 Dec;66(6):2264-78.

12.

Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats.

Liu M, Gu M, Wu Y, Zhu P, Zhang W, Yin C, Zhang WJ.

J Surg Res. 2009 Nov;157(1):e117-27. doi: 10.1016/j.jss.2008.10.018. Epub 2008 Nov 24.

PMID:
19589538
13.

A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.

Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, Kretzler M, Strutz F, Mack M, Gröne HJ, Onuffer J, Horuk R, Nelson PJ, Schlöndorff D.

J Clin Invest. 2002 Jan;109(2):251-9.

14.

Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.

Schaier M, Vorwalder S, Sommerer C, Dikow R, Hug F, Gross ML, Waldherr R, Zeier M.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F769-80. doi: 10.1152/ajprenal.90530.2008. Epub 2009 Jun 17.

15.

Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.

Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei GP, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD.

J Biol Chem. 2000 Jun 23;275(25):19000-8.

16.

Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.

Gao W, Topham PS, King JA, Smiley ST, Csizmadia V, Lu B, Gerard CJ, Hancock WW.

J Clin Invest. 2000 Jan;105(1):35-44.

17.

A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation.

Futamatsu H, Suzuki J, Koga N, Adachi S, Kosuge H, Maejima Y, Haga T, Hirao K, Horuk R, Isobe M.

J Mol Cell Cardiol. 2006 Jun;40(6):853-61. Epub 2006 May 12.

PMID:
16698032
19.

Chemokine receptor CCR1: a new target for progressive kidney disease.

Ninichuk V, Anders HJ.

Am J Nephrol. 2005 Jul-Aug;25(4):365-72. Epub 2005 Jul 22. Review.

20.

Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats.

Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U.

Transplantation. 2005 Mar 27;79(6):655-61.

PMID:
15785371

Supplemental Content

Support Center